Trial Profile
A Phase III, Randomised, Double-blind, Placebo-controlled, Multi-centre, International Study of MEDI4736 as Sequential Therapy in Patients With Locally Advanced, Unresectable Non-Small Cell Lung Cancer (Stage III) Who Have Not Progressed Following Definitive, Platinum-based, Concurrent Chemoradiation Therapy (PACIFIC)
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 12 Dec 2023
Price :
$35
*
At a glance
- Drugs Durvalumab (Primary)
- Indications Non-small cell lung cancer
- Focus Registrational; Therapeutic Use
- Acronyms PACIFIC
- Sponsors AstraZeneca; AstraZeneca AB; AstraZeneca KK
- 21 Sep 2023 Status changed from active, no longer recruiting to completed.
- 28 Jun 2023 Planned End Date changed from 30 Jun 2023 to 31 Jul 2023.
- 23 Feb 2023 Results of post-hoc subgroup analysis (At data cut-off January 11, 2021) assessing the efficacy and safety analysis from a subgroup of patients with EGFRm non-small cell lung cancer from PACIFIC, published in the Journal of Thoracic Oncology.